Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yibing Lu

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Obesity (Silver Spring, Md.)|May 29, 2025
Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN studyLin Zhao, Hong Chen, Zhifeng Cheng, et al.
Journal of Thrombosis and Thrombolysis|August 18, 2016
An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic strokeLi Zhang, Junsu Yang, Qiang Xue, et al.
American Journal of Translational Research|April 12, 2018
MicroRNA-134-5p promotes high glucose-induced podocyte apoptosis by targeting bcl-2Xiaoxiao Qian, Juan Tan, Ling Liu, et al.
Journal of Diabetes and Its Complications|December 24, 2016
Microarray analysis of long noncoding RNA expression patterns in diabetic nephropathySheng Chen, Chenglong Dong, Xiaoxiao Qian, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 19, 2023
Association of Serum Bile Acid and Unsaturated Fatty Acid Profiles with the Risk of Diabetic Retinopathy in Type 2 Diabetic PatientsSusu Feng, Lin Guo, Sijing Wang, et al.
Diabetes, Obesity & Metabolism|June 28, 2022
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trialXiaoyong Yuan, Xiaohui Guo, Junqing Zhang, et al.
Journal of Diabetes Science and Technology|June 12, 2026
Performance and Safety of a 15-Day Real-Time Continuous Glucose Monitoring System in Chinese Adults With Diabetes: A Multicenter TrialMei Zhang, Yibing Lu, Hongwei Ling, et al.
Diabetologia|July 10, 2024
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trialLinong Ji, Rikke M Agesen, Stephen C Bain, et al.
Experimental Cell Research|April 18, 2015
Heme oxygenase-1 enhances autophagy in podocytes as a protective mechanism against high glucose-induced apoptosisChenglong Dong, Haining Zheng, Shanshan Huang, et al.
Diabetes, Obesity & Metabolism|August 13, 2021
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulinYu Pei, Bue R Agner, Bin Luo, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Obesity (Silver Spring, Md.)|May 29, 2025
Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN studyLin Zhao, Hong Chen, Zhifeng Cheng, et al.
Journal of Thrombosis and Thrombolysis|August 18, 2016
An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic strokeLi Zhang, Junsu Yang, Qiang Xue, et al.
American Journal of Translational Research|April 12, 2018
MicroRNA-134-5p promotes high glucose-induced podocyte apoptosis by targeting bcl-2Xiaoxiao Qian, Juan Tan, Ling Liu, et al.
Journal of Diabetes and Its Complications|December 24, 2016
Microarray analysis of long noncoding RNA expression patterns in diabetic nephropathySheng Chen, Chenglong Dong, Xiaoxiao Qian, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 19, 2023
Association of Serum Bile Acid and Unsaturated Fatty Acid Profiles with the Risk of Diabetic Retinopathy in Type 2 Diabetic PatientsSusu Feng, Lin Guo, Sijing Wang, et al.
Diabetes, Obesity & Metabolism|June 28, 2022
Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trialXiaoyong Yuan, Xiaohui Guo, Junqing Zhang, et al.
Journal of Diabetes Science and Technology|June 12, 2026
Performance and Safety of a 15-Day Real-Time Continuous Glucose Monitoring System in Chinese Adults With Diabetes: A Multicenter TrialMei Zhang, Yibing Lu, Hongwei Ling, et al.
Diabetologia|July 10, 2024
Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trialLinong Ji, Rikke M Agesen, Stephen C Bain, et al.
Experimental Cell Research|April 18, 2015
Heme oxygenase-1 enhances autophagy in podocytes as a protective mechanism against high glucose-induced apoptosisChenglong Dong, Haining Zheng, Shanshan Huang, et al.
Diabetes, Obesity & Metabolism|August 13, 2021
DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulinYu Pei, Bue R Agner, Bin Luo, et al.
Pageof 6